Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indolepropionic acid - ViroPharma Incorporated

Drug Profile

Indolepropionic acid - ViroPharma Incorporated

Alternative Names: IN-OX1; Indole-3-propionic acid; IPA - ViroPharma Incorporated; OX-1; Oxigon; SHP 22; SHP-622; VP-20629

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New York University; University of South Alabama
  • Developer Intellect Neurosciences; ViroPharma Incorporated
  • Class Antidementias; Indoles; Neuroprotectants; Propionic acids; Small molecules
  • Mechanism of Action Amyloid inhibitors; Antioxidants; Chelating agents; Free radical scavengers; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Friedreich's ataxia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Friedreich's ataxia in USA (PO, Capsule)
  • 01 Jul 2015 Shire ViroPharma completes a phase I trial in Friedreich's ataxia in USA (NCT01898884)
  • 11 Mar 2014 ViroPharma is now called Shire ViroPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top